NCT01719627View on ClinicalTrials.gov

First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

January 31, 2015

Conditions
HIV
Interventions
DRUG

Maraviroc

Unique dose of Maraviroc 300mg

DRUG

TVD 300/200 QD

TVD 300/200 QD during 7 days

DRUG

Maraviroc

Unique dose of Maraviroc 600mg

Trial Locations (1)

08916

Germans Trias i Pujol Hospital, Badalona

All Listed Sponsors
lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

NCT01719627 - First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers | Biotech Hunter | Biotech Hunter